Supplementary Materials Information

Ciprofloxacin conjugated to diphenyltin(IV); A novel formulation with enhanced antimicrobial activity.

M.P. Chrysouli[a], C.N. Banti[a],*, N. Kourkoumelis[b], E.E.Moushi[c], A.J. Tasiopoulos[d], A. Douvalis[e], C. Papachristodoulou[f], A.G. Hatzidimitriou[g],T. Bakas[e], S.K. Hadjikakou[a,h],*

[a] Inorganic and Analytical Chemistry, Department of Chemistry, University of Ioannina, 45110 Ioannina, Greece

[b] Medical Physics Laboratory, Medical School, University of Ioannina, Greece

[c] Department of Life Sciences, The School of Sciences, European University Cyprus, Cyprus

[d] Department of Chemistry, University of Cyprus, 1678 Nicosia, Cyprus

[e] Mössbauer Spectroscopy and Physics of Material Laboratory, Department of Physics, University of Ioannina, Greece

[f] Department of Physics, University of Ioannina, Greece

[g] Department of Chemistry, Aristotle University of Thessaloniki, Greece;

[h] University Research Center of Ioannina (URCI), Institute of Materials Science and Computing, Ioannina, Greece

*All correspondence should be addressed to:

Dr. C.N. Banti (Postdoctoral Fellow); email: cbanti@uoi.gr

Dr. S.K. Hadjikakou (Professor); e-mail: shadjika@uoi.gr; tel. x30-26510-08374, x30-26510-08362



Figure S1. IR spectra of **CIPTIN, HCIP·HCl** and **DPTD**



Figure S2. The simulated XRPD pattern (_____) using single crystal XRD data, which is overlaying the experimental one (_____), adequately resembles the experimental pattern.



Figure S3. Thermal analysis diagram of **CIPTIN**



Figure S4. UV spectra of **CIPTIN** in DMSO solution 1.5×10^{-5} M at 0, 24 and 48 hours



Figure S5. UV spectra of **CIPTIN** in DMSO/water solution 1.5×10^{-5} M at 0, 24 and 48 hours



Figure S6. ^{1}H-NMR spectra of **CIPTIN** in dmso-d_6 at 0 and 96 hours.



Figure S7. ^{1}H-NMR spectra of **CIPTIN**, **HCIP•HCl** and **DPTD** in DMSO-d$_6$



Figure S8. ESI-MS of **CIPTIN** in MeOH solution.



(A)



(B)



(C)



(D)

Figure S9. Minimum Inhibitory Concentration of **CIPTIN** against *PAO1* (**A**), *E. coli* (**B**), *S. aureus* (**C**) and *S. epidermidis* (**D**)



Figure S10. Minimum Inhibitory Concentration of **HCIP·HCl** against *E. coli*



(A)



(B)



(C)



(D)

Figure S11. Minimum Inhibitory Concentration of **HCIP** against *PAO1* (**A**), *E. coli* (**B**), *S. aureus* (**C**) and *S. epidermidis* (**D**)



(A)



(B)



(C)



(D)

Figure S12. Minimum Inhibitory Concentration of **DPTD** against *PAO1* (**A**), *E. coli* (**B**), *S. aureus* (**C**) and *S. epidermidis* (**D**)



Figure S13. Results from MBC assay with **CIPTIN** against *PAO1* (A), *E. coli* (B), *S. aureus* (C) and *S. epidermidis* (D)



Figure S14. Results from MBC assay with **HCIP·HCl** against *E. coli*



Figure S15. Results from MBC assay with **HCIP** against *PAO1* (A), *E. coli* (B), *S. aureus* (C) and *S. epidermidis* (D)



Figure S16. Results from MBC assay with **DPTD** against *PAO1* (A), *E. coli* (B), *S. aureus* (C) and *S. epidermidis* (D)



Figure S17. Inhibition zones of **HCIP** against *PAO1* (A), *E. coli* (B), *S. aureus* (C) and *S. epidermidis* (D) and that of **HCIP·HCl** against *E. coli* (E)



Figure S18. Inhibition zones of **DPTD** against *PAO1* (A), *E.coli* (B), *S. aureus* (C) and *S. Epidermidis* (D)



Figure S19 Biofilm inhibition (%) of *P. aeruginosa* and *S. aureus* versus pC=-log(C) (M) of **HCIP**.